EUROIMMUN Logo
Find
X

What are you looking for?

Filter for products in our complete portfolio

Product finder

Worldwide
X
EUROIMMUN worldwide

This website provides an overview of the business activities and products of EUROIMMUN AG worldwide. Not all products are registered and approved in all countries or regions. Please contact your country representative for product availability and information

EUROIMMUN branches

Choose your country

Europe

North America

South & Central America

Asia

Middle East & Africa

EUROIMMUN Logo
Español
English

Diagnóstico de Chikungunya

To date, approximately 350,000 cases of chikungunya virus infection and over 140 associated deaths have been reported in 20241.

According to the WHO, chikungunya virus is present in over 110 countries and about 4 billion people worldwide are at risk of infection 2.

Although the disease reveals a very low case fatality rate of less than 1%, a significant number of patients develop long-lasting or even chronic joint pain, similar to arthritis, which has a severe impact on the patient’s quality of life3.

Apart from joint pain, chikungunya virus infection causes very similar symptoms to dengue and Zika, which is why it is often misdiagnosed2.

1 ECDC: Chikungunya worldwide overview, situation update as of 31 of July 2024
2 WHO: Chikungunya fact sheet as of 08 of December 2022
3 WHO: Chikungunya virus disease outbreak, situation update as of 03 of May 2023

Diagnóstico de infecções com a EUROIMMUN

Como o vírus chikungunya causa doenças febris com sintomas semelhantes aos de outros arbovírus, nosso portfólio de testes inclui vários ensaios para ajudar no diagnóstico confiável da infecção pelo vírus chikungunya e permitir a diferenciação das infecções pelos vírus da dengue e Zika.

Outros parâmetros arbovirais importantes:

Dengue        Zika

Pensar globalmente - Agir localmente
Com mais de 35 anos de experiência no campo de diagnósticos laboratoriais, desenvolvemos e distribuímos soluções completas de diagnóstico (globalmente) que são adaptadas às suas necessidades (locais). Trabalhando em conjunto com as autoridades científicas e de saúde locais, ficamos atentos a novos e/ou urgentes eventos de infecção e oferecemos soluções adequadas para o diagnóstico de doenças infecciosas em todo o mundo. Com nosso inigualável desenvolvimento e produção internos de sistemas de teste de diagnóstico, bem como nossas soluções de automação e software, somos capazes de responder rapidamente a surtos de infecção pequenos (locais) e grandes (globais), fornecendo suporte quando e onde for necessário.
Thinking globally – acting locally

Importante para o diagnóstico diferencial de doenças febris arbovirais

ELISA

IFA (ensaio de imunofluorescência indireta)

  • Anti-Chikungunya virus IIFT (IgM, IgG)
    → Data sheet (PDF)
  • Arbovirus fever mosaic 2 (IgG, IgM)
    → Data sheet (PDF)
  • Arbovirus Profil 3 (IgG, IgM)
    código FI 293a-1005 G / M, FI 2668-1005-1 G / M, FI 2668-1005-3 G / M

Saiba mais sobre nosso portfólio de testes em:

Emerging diseases

 
 

Soluções da EUROIMMUN para infecções arbovirais

nas Américas

 
 

Mais informações

Contato

Se tiver alguma dúvida, não hesite em entrar em contato conosco:

EUROIMMUN Brazil

Ou entre em contato com sua pessoa de contato local

Encontre seu distribuidor local

Editorial: Innovations for infectious diseases diagnostics

EUROIMMUN offers an extensive range of test systems for infection diagnostics, including serological
assays for antibody determination and PCR-based tests for direct pathogen detection. For the growing
field of emerging diseases, EUROIMMUN boasts one of the largest portfolios of antibody tests
worldwide to support diagnosis and surveillance of upsurging viral and parasitic infections.
Read more

Featured in PPC, April 2024

Editorial: Serological differentiation of Zika from dengue virus infections

SEROLOGICAL DIAGNOSIS OF ZIKA virus (ZIKV) infections is challenging due to the high cross reactivity between flaviviruses. Test systems utilising virus-specific antigen can overcome this obstacle. A novel anti-ZIKV ELISA based on a highly specific antigen is devoid of cross reactivity with dengue virus (DENV) antibodies, and provides highly specific and sensitive ZIKV diagnostics.
Read more

Featured in MedLab Daily Dose, March 2017

 
Back to top
Contact person on site
Please click on a country or enter yours
North America
South & Central America
Europe
Asia
Oceania
Middle East & Africa